BioMarin Pharmaceutical Bets on Amicus Growth as VOXZOGO Competition Concerns Mount
BioMarin Pharmaceutical is focusing on integrating its Amicus acquisition and advancing its rare-disease pipeline to drive future growth, while addressing investor worries about competition for its VOXZOGO treatment. The company projects significant revenue and EPS growth by 2026, with the Amicus therapies expected to surpass previous peak sales estimates. BioMarin also emphasized that concerns over VOXZOGO competition are exaggerated, as the primary competitive threat affects only a small portion of its total revenue, and the company is pursuing new indications and pipeline advancements.
A BioMarin (BMRN) officer plans to sell 5,147 shares valued at about $303K.
Gregory R. Friberg, an officer at BioMarin Pharmaceutical Inc. (BMRN), intends to sell 5,147 common shares, acquired through restricted stock vesting on September 30, 2026. The proposed sale, with an approximate date of November 18, 2026, has an aggregate market value of $302,710.44. Fidelity Brokerage Services LLC is listed as the broker for this transaction.
BMRN: Amicus growth, VOXZOGO expansion and 2027 pipeline catalysts underpin the outlook
BioMarin Pharmaceutical Inc. (BMRN) sees significant growth opportunities driven by its Amicus assets and VOXZOGO, alongside a diversified portfolio of nine products reaching 80 countries. Future catalysts in 2027 include a hypochondroplasia review and data from BMN 333 and BMN 440, which are expected to further strengthen the company's financial outlook.
Weekly Recap: Q3 revenue hits $1 billion and VOXZOGO decision due in 2027
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported a significant 32% year-over-year increase in Q3 revenue, reaching approximately $1 billion for the first time. Key updates include an expected decision on expanding VOXZOGO to hypochondroplasia by May 2027, and anticipated Phase 1/2 data for BMN 440 next year. The company's average 12-month price target was slightly adjusted, with analysts maintaining a Buy consensus.
BioMarin Pharmaceutical Inc. Stock 12‑Month Price Target Cut to $90.19, Implies 59% Upside
BioMarin Pharmaceutical Inc.'s average 12-month price target has been lowered slightly from $90.81 to $90.19, according to estimates from 26 analysts. This updated target suggests a potential upside of approximately 59% based on the Nov. 12 closing price, with individual forecasts ranging from $60 to $120 per share. The consensus rating for the stock remains a "Buy" from 31 covering analysts.
BioMarin Pharmaceutical Hits $1 Billion Revenue Milestone, Advances Rare-Disease Pipeline
BioMarin Pharmaceutical achieved a significant milestone, reaching $1 billion in third-quarter revenue, a 32% increase driven largely by its metabolic-disease segment and the Amicus acquisition. The company is actively integrating Amicus Therapeutics, aiming for $220 million in annual operating expense synergies by 2028, and is advancing several rare-disease drug candidates, including BMN 440 for hypophosphatasia, BMN 333 for achondroplasia, and BMN 820 for focal segmental glomerulosclerosis, with key data releases anticipated in the coming years. BioMarin also continues to explore expansion opportunities for existing therapies like VOXZOGO and is focused on reducing leverage while acquiring new clinical-stage assets.
BMRN: Amicus growth funds a rebuilt pipeline, with key data milestones through 2028
BioMarin Pharmaceutical Inc. (BMRN) reported strong Q3 revenue growth of 32%, topping $1 billion, driven by metabolic conditions and Amicus assets. The company is targeting roughly $220 million in synergies by 2028 and has several pipeline milestones, including BMN 440 and BMN 333 data in 2027 and BMN 820 results in 2028. This information was based on the Stifel 2026 Healthcare Conference audio transcript from November 11, 2026.
BMRN: Record Q3 revenue and pipeline expansion set up key readouts through 2028
BioMarin Pharmaceutical Inc. (BMRN) achieved record Q3 revenue of $1 billion, a 32% increase, while also expanding its rare-disease assets through Amicus, adding approximately $220 million in targeted synergies. The company's pipeline includes upcoming data readouts for BMN 440 HPP next year, BMN 333 Phase II data in 2027, and BMN 820 results in 2028. This information is based on the Stifel 2026 Healthcare Conference audio transcript from November 11, 2026.
Weekly Recap: Q3 revenue up, 2026 guidance cut and analyst target cuts
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported a 32% rise in Q3 revenue to $1.025 billion, but also a GAAP loss of $123 million, leading to a cut in its 2026 revenue and EPS guidance. Following this, four analysts reduced their price targets for BMRN while maintaining their ratings. The company also acquired BMN 440 for hypophosphatasia treatment, discontinued BMN 401, and released positive five-year results for Pombiliti + Opfolda in Pompe disease.
Biopharma Co. Reports First Quarterly Revenue Above US$1 Billion as Acquisition Expands Portfolio
BioMarin Pharmaceutical Inc. reported its first-ever quarterly revenue exceeding US$1 billion in Q3 2026, reaching US$1.025 billion, driven by its Amicus acquisition and growth in existing therapies. Despite this milestone, the company lowered its full-year 2026 revenue and non-GAAP EPS guidance due to international order timing and acquisition-related charges. BioMarin is also expanding its Fabry disease pipeline with a new investigational treatment and advancing regulatory applications for VOXZOGO.
Four undervalued healthcare stocks with the highest year-over-year CapEx growth
Amidst a cautious US stock market, four healthcare companies are highlighted for their attractive valuations and high year-over-year capital expenditure (CapEx) growth. Fortrea Holdings Inc. leads the list with 126.21% CapEx growth, followed by BioMarin Pharmaceutical Inc., CVS Health Corporation, and Centene Corporation. These companies are drawing attention from investors assessing trends in pharmaceutical, healthcare services, and managed-care businesses.
H.C. Wainwright reiterates BioMarin stock rating at Neutral
H.C. Wainwright has reiterated a Neutral rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) with a $60.00 price target, despite the stock trading below this target. The company reported Q3 2026 revenue of $1.025 billion, a 3.5% increase, but lowered its full-year VOXZOGO guidance due to international shipment timing. Other analysts, including Cantor Fitzgerald and Oppenheimer, have also provided updated ratings and price targets following these results.
Three talks by rare-disease drugmaker BioMarin will be available live online.
BioMarin Pharmaceutical (NASDAQ: BMRN) announced that its management will present at three investor conferences in November 2026: the Stifel Healthcare Conference, UBS Global Biopharma Conference, and Jefferies Global Healthcare Conference. Live audio webcasts of these presentations will be available on the company's investor website, with archives accessible for a limited time. BioMarin, founded in 1997, is a global biotechnology company focused on genetically defined rare diseases.
BioMarin to Participate in Upcoming Investor Conferences
BioMarin Pharmaceutical Inc. announced its management will present at three upcoming investor conferences in November: the Stifel Healthcare Conference, UBS Global Biopharma Conference, and Jefferies Global Healthcare Conference. Audio webcasts of these presentations will be available live and archived on BioMarin's investor relations website. The company, founded in 1997, is a global biotechnology company focused on delivering medicines for people living with genetically defined conditions.
H.C. Wainwright Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)
H.C. Wainwright analyst Mitchell Kapoor reiterated a Neutral rating and a $60.00 price target for BioMarin Pharmaceutical Inc. (BMRN). The analyst expressed caution regarding VOXZOGO's U.S. retention due to potential oral competition before hypochondroplasia revenue contributes. The revised 2026 VOXZOGO guidance reflects international shipment timing, although management anticipates growth in 2027.
Biomarin Pharmaceutical (BMRN) Stock Price, Chart & Analysis
This article provides a detailed analysis of Biomarin Pharmaceutical (BMRN) stock, covering its current price ($55.66), market capitalization ($11.12B), and key financial metrics as of November 4, 2026. It includes quality, value, and growth scores, answers frequently asked questions about the company, and presents an "At a Glance" section summarizing various financial ratios and an in-depth analysis of its valuation, growth, margins, debt, and dividend policy. The article also features a "Belegger score" based on the methods of Buffett and Lynch, outlining different scenarios for future price performance.
Revenue tops $1B at BioMarin (BMRN), but its quarterly net loss widens.
BioMarin Pharmaceutical Inc. reported a significant increase in third-quarter 2026 revenue to $1,024.6 million, up from $776.1 million in the prior year, primarily driven by sales of GALAFOLD and POMBILITI + OPFOLDA following the Amicus acquisition. However, the company's net loss widened to $122.8 million from $30.7 million in Q3 2025, largely due to higher acquired in-process R&D expenses, increased interest expense from acquisition financing, and amortization of acquired intangible assets. Despite the widening loss, BioMarin continues to expand its pipeline through new licensing agreements and aims to grow its commercial portfolio.
Sidley Represents Hanmi Pharm and Green Cross Biopharma in Licensing Agreement With BioMarin
Sidley represented GC Biopharma Corp. and Hanmi Pharm Co., Ltd. in an exclusive licensing agreement with BioMarin Pharmaceutical Inc. for LA-GLA, a next-generation therapy for Fabry disease. The agreement is valued at up to US$475 million, including an upfront payment and milestone payments. BioMarin will lead global development and commercialization, while GC Biopharma and Hanmi Pharm will handle regulatory approval and commercialization in South Korea.
HC Wainwright & Co. maintains BioMarin Pharmaceutical at Neutral, keeps price target at $60
HC Wainwright & Co. has reiterated its Neutral rating for BioMarin Pharmaceutical (BMRN), maintaining a price target of $60. This price target suggests a 4.5% upside from the stock's closing price on November 2nd. Other recent analyst actions on BioMarin Pharmaceutical show price targets ranging from $60 to $122.
Cantor Fitzgerald reiterates Overweight on BioMarin stock at $86
Cantor Fitzgerald reiterated an Overweight rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) with an $86 price target, noting the stock is currently undervalued at $57.44 with a Fair Value of $76.24. Despite the company's Q3 revenue beating estimates, it lowered its fiscal 2026 revenue guidance due to uncertainty in international Voxzogo sales timing, a factor Cantor Fitzgerald views as a revenue recognition issue rather than a fundamental business concern. Several other analysts have also adjusted their price targets for BioMarin in response to the mixed Q3 results and revised outlook.
BioMarin Pharmaceutical Q3 Earnings Call Highlights
BioMarin Pharmaceutical reported its first-ever quarterly revenue above $1 billion in Q3, driven by strong growth in its rare-disease portfolio and products acquired from Amicus Therapeutics. Despite this performance, the company lowered its full-year 2026 revenue guidance to $3.8 billion to $3.9 billion due to deferred international orders and Middle East conflict-related disruptions. BioMarin also added a new investigational Fabry disease program, BMN 450, to its pipeline and highlighted ongoing clinical developments for other therapies.
BioMarin reports Q3 revenue beat but cuts full-year outlook
BioMarin Pharmaceutical Inc. reported a third-quarter revenue of $1.025 billion, exceeding estimates, but earnings per share matched expectations at $0.23. The company subsequently lowered its full-year revenue guidance by $50 million and its fiscal 2026 earnings guidance due to business development deals and a potential shift in a large order. Despite these reductions, BioMarin noted faster-than-expected cost synergy realization from the Amicus acquisition.
Stifel cuts BioMarin stock price target to $66 on growth concerns
Stifel has reduced its price target for BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $66 from $70, while maintaining a Hold rating due to concerns about growth and competition for its Voxzogo product. The adjustment follows BioMarin's mixed Q3 2026 earnings, where some products beat expectations but others, including Voxzogo, underperformed. Despite challenges, BioMarin achieved its first quarter with over $1 billion in revenue, but revised its full-year outlook downward due to acquisition charges and order timing.
BioMarin Beats Q3 Revenue Forecasts but Cuts 2026 Outlook on Voxzogo Timing and Deal Costs
BioMarin Pharmaceutical Inc. exceeded third-quarter revenue forecasts due to strong sales of Galafold, Vimizim, and PomOp. However, the company lowered its full-year 2026 revenue and earnings guidance, primarily attributing the cut to uncertainty around a potential Voxzogo order delay and costs associated with the Alesta acquisition and BMN 450 licensing deals. Despite the revised outlook, BioMarin anticipates faster-than-expected cost synergies from the Amicus acquisition, projecting it to become earnings-accretive within nine months.
BioMarin Pharmaceutical Inc. (BMRN.VI) stock price, news, quote and history
BioMarin Pharmaceutical Inc.'s stock (BMRN.VI) closed at 48.74 EUR on November 3, 2026, marking a -5.73% decline. The company's YTD return is -4.24%, significantly underperforming the S&P 500, which posted a +10.57% YTD return. Investors can access the Q3 2026 earnings call replay for further insights.
BioMarin reports Q3 revenue beat but cuts full-year outlook By Investing.com
BioMarin Pharmaceutical Inc. reported third-quarter revenue of $1.025 billion, surpassing estimates, while earnings per share matched expectations. Despite the revenue beat driven by stronger performance in certain drugs, the company cut its full-year Voxzogo guidance and overall revenue outlook, citing potential order shifts and reductions in its metabolic conditions business. The company also lowered its fiscal 2026 earnings guidance, primarily due to business development deals, though it noted faster-than-expected cost synergy realization from an acquisition.
Form 8K Biomarin Pharmaceutical Inc For: 2 November By Investing.com
This article from Investing.com announces the filing of a Form 8K by Biomarin Pharmaceutical Inc. on November 2nd. The brief mention indicates a regulatory filing, typically used to disclose significant events to shareholders. The article is very concise, primarily serving as an alert for this corporate action.
BioMarin Pharma (BMRN) Tops Q3 EPS by 11c
BioMarin Pharma (BMRN) reported strong third-quarter results, exceeding analyst estimates for both earnings per share and revenue. The company posted an EPS of $0.23, significantly higher than the $0.12 consensus, and revenues reached $1.03 billion, slightly above the $1.02 billion expectation. This performance indicates a positive financial quarter for BioMarin Pharma.
BioMarin Pharmaceutical (BMRN) Could Be 21% Undervalued On Mixed Q3 Guidance Cut
BioMarin Pharmaceutical (BMRN) reported mixed Q3 2026 results, with adjusted profit exceeding expectations but sales falling short, leading to lowered full-year guidance. Despite short-term share price dips, the company is seen as potentially 21% undervalued, with a fair value of $73, driven by its rare disease franchise and pricing power. Investors are encouraged to assess the underlying data, rewards, and risks.
Earnings call transcript: BioMarin tops Q3 2026 estimates, but shares fall
BioMarin Pharmaceutical reported Q3 2026 adjusted earnings and revenue above Wall Street expectations, with non-GAAP EPS of $0.23 and revenue of $1.03 billion, marking the first time quarterly sales topped $1 billion. Despite this, shares fell in after-hours trading due to a lowered full-year outlook, acquisition-related charges, and order timing delays from a single international customer. The company, however, emphasized strong underlying business performance and pipeline expansion.
Biomarin Pharmaceutical Q3 2026 Earnings Call Transcript
BioMarin Pharmaceutical (NASDAQ: BMRN) reported strong third-quarter 2026 financial results, with 32% year-over-year revenue growth, exceeding $1 billion for the first time. The company highlighted significant growth in its Metabolic Conditions business, driven by products like Galafold and Pombiliti and Opfolda, and discussed pipeline expansion with new investigational assets. BioMarin also updated its full-year 2026 revenue guidance to $3.8-$3.9 billion due to order timing and geopolitical factors, while accelerating cost synergies from the Amicus acquisition.
BioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass Estimates
BioMarin Pharmaceutical (BMRN) reported Q3 earnings of $0.23 per share, significantly beating the Zacks Consensus Estimate of a $0.09 loss per share, though revenues of $1.02 billion slightly missed expectations. The company has surpassed EPS estimates three times and revenue estimates three times over the past four quarters. Despite outperforming earnings estimates, BioMarin's stock has lost 1.6% year-to-date, contrasting with the S&P 500's 10.7% gain.
BioMarin Reports Third Quarter 2026 Financial and Operating Results
BioMarin Pharmaceutical Inc. announced strong financial results for the third quarter of 2026, with total revenues increasing 32% year-over-year to $1.025 billion, marking the first time quarterly revenue exceeded $1 billion. This growth was primarily driven by a 44% increase in metabolic conditions and a 12% increase in skeletal conditions, bolstered by recent acquisitions and increased demand for their medicines. The company also updated its full-year 2026 guidance and highlighted pipeline advancements, including new investigational treatments for Fabry disease and hypochondroplasia.
BioMarin Reports Third Quarter 2026 Financial and Operating Results
BioMarin Pharmaceutical Inc. announced strong financial results for the third quarter of 2026, with total revenues increasing 32% year-over-year to $1.025 billion, marking the first time quarterly revenue exceeded $1 billion. This growth was driven by a diversified portfolio, including recent acquisitions and increased demand for metabolic and skeletal conditions therapies. The company also updated its full-year 2026 guidance, reflecting order timing uncertainty and the impact of acquired in-process R&D charges, while continuing to expand its pipeline with new investigational assets.
BioMarin Pharmaceutical Inc. (BMRN) Stock forecasts
Argus has lowered its target price for BioMarin Pharmaceutical Inc. (BMRN) to $53.00, according to a report from October 28, 2026. BioMarin is a global biotechnology company specializing in therapies for rare genetic diseases. The current price for BMRN stock is $58.51.
BioMarin Pharmaceutical Inc. (BMRN) Seasonal returns chart
The article provides a seasonal returns chart for BioMarin Pharmaceutical Inc. (BMRN), displaying average monthly price returns from 2016 to 2026. It also includes current stock information, recent trading activity, and a reminder about the company's Q3 2026 earnings call.
GC Biopharma, Hanmi Pharmaceutical License Fabry Disease Drug to BioMarin for approximately $478 Million
South Korea's GC Biopharma and Hanmi Pharmaceutical have licensed their co-developed Fabry disease drug candidate, HM15421/GC1134A, to U.S.-based BioMarin for up to $475 million, including a $70 million upfront payment. BioMarin gains exclusive global development and commercialization rights, excluding South Korea, for the drug, which is designed as a once-monthly subcutaneous injection. This deal expands BioMarin's Fabry disease portfolio and aims to provide treatment options for patients not suitable for existing therapies like Galafold.
BioMarin Sees $1.50 Q3 EPS Hit From Alesta Costs Ahead of Results
BioMarin Pharmaceutical Inc. anticipates a $1.50 reduction in third-quarter 2026 diluted earnings per share due to costs from its Alesta Therapeutics acquisition, which includes $283 million in pretax acquired R&D expense. The company also projects a full-year 2026 impact of $1.55 per share from Alesta-related charges. BioMarin plans to update its 2026 financial guidance when it discusses its Q3 results on November 2nd.
BioMarin licenses Fabry disease therapy for $70M upfront
BioMarin Pharmaceutical Inc. has entered into an exclusive worldwide license agreement with GC Biopharma Corp. and Hanmi Pharm Co., Ltd. for HM15421/GC1134A, an investigational enzyme replacement therapy for Fabry disease. BioMarin will make an upfront payment of $70 million, with potential additional payments of up to $405 million and tiered royalties. The agreement grants BioMarin commercialization rights globally, excluding Korea, and responsibility for further clinical development, manufacturing, and commercialization outside of Korea.
BioMarin signs deal worth $475 M with Korea's GC Biopharma and Hanmi Pharm for potential treatment of Fabry Disease
US-based BioMarin Pharmaceutical Inc. has entered into an exclusive worldwide license agreement with South Korea's GC Biopharma Corp. and Hanmi Pharm Co. to develop and commercialize HM15421/GC1134A, a potential treatment for Fabry disease. The deal is worth up to $475 million, including a $70 million upfront payment and up to $405 million in development and commercial milestones, plus tiered royalties. This investigational long-acting enzyme replacement therapy, currently in Phase 1/2 clinical trials, aims to be the first subcutaneous option for Fabry disease.
BioMarin licenses ex-Korea rights to Fabry enzyme therapy for USD 70m upfront
BioMarin Pharmaceutical Inc. has licensed exclusive worldwide rights, excluding Korea, to HM15421/GC1134A, an investigational Fabry disease enzyme replacement therapy, from GC Biopharma Corp. and Hanmi Pharm Co., Ltd. The deal includes a $70 million upfront payment and up to $405 million in milestones plus royalties. BioMarin will be responsible for clinical development, manufacturing, and commercialization outside Korea after the ongoing Phase I/II study.
GC Biopharma, Hanmi strike Fabry drug deal worth up to $475 mn with BioMarin
South Korean pharmaceutical companies GC Biopharma Corp. and Hanmi Pharmaceutical Co. have entered a licensing agreement with BioMarin Pharmaceutical Inc. for an experimental Fabry disease treatment. The deal is valued at up to $475 million, with an upfront payment of $70 million. This agreement contributes to exceeding 20 trillion won ($15 billion) in total licensing deals for Korean drugmakers this year.
BioMarin licenses Fabry disease therapy for $70M upfront By Investing.com
BioMarin Pharmaceutical Inc. has entered into an exclusive worldwide license agreement with GC Biopharma Corp. and Hanmi Pharm Co., Ltd. for HM15421/GC1134A, an investigational enzyme replacement therapy for Fabry disease. BioMarin will make an upfront payment of $70 million, with potential for an additional $405 million in milestones and royalties. This agreement grants BioMarin commercialization rights globally, excluding Korea, and responsibility for further development of the long-acting, subcutaneous treatment.
A Fabry drug deal could pay two companies up to $405 million if milestones are met
BioMarin Pharmaceutical has entered into an exclusive worldwide license agreement with GC Biopharma and Hanmi Pharm for HM15421/GC1134A, an investigational enzyme replacement therapy for Fabry disease. The deal includes a $70 million upfront payment and up to $405 million in potential development and commercial milestone payments, plus tiered royalties. This agreement expands BioMarin's Fabry disease portfolio and offers a potential new subcutaneous treatment option.
BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease
BioMarin Pharmaceutical Inc. has secured an exclusive worldwide license agreement with GC Biopharma Corp. and Hanmi Pharm Co., Ltd. for HM15421/GC1134A, a potential next-generation enzyme replacement therapy for Fabry disease. This investigational, long-acting, subcutaneous treatment could be the first of its kind for Fabry disease patients, expanding BioMarin's portfolio following its acquisition of Amicus. The agreement includes an upfront payment of $70 million, with additional milestone and royalty payments for GC and Hanmi.
BioMarin schedules third-quarter results. BioMarin stock is valued at USD 10.7 billion
BioMarin Pharmaceutical Inc. is scheduled to discuss its third-quarter 2026 results on November 2, 2026, at 4:30 p.m. ET. The company's stock had a market value of USD 10.7 billion as of October 27, 2026, with its second-quarter revenue reaching USD 989.7 million, an increase of 19.9 percent year over year. Analysts have reiterated a Neutral rating but cut third-quarter EPS estimates, making the upcoming earnings call crucial for assessing the balance between Amicus acquisition integration costs and revenue growth.
Baird reiterates Neutral rating on BioMarin stock at $65
Baird has reiterated a Neutral rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) with a $65 price target, despite the stock appearing undervalued at $55.75. The firm adjusted its financial model due to Alesta-related acquired research and development costs and revised operating expense expectations ahead of BioMarin's third-quarter 2026 earnings. BioMarin has also recently discontinued development of Voxzogo for Noonan syndrome and expanded its board of directors.
BioMarin Pharmaceutical (BMRN): Amicus Acquisition Accelerates Revenue Growth
BioMarin Pharmaceutical's acquisition of Amicus Therapeutics for $4.8 billion has significantly boosted its revenue growth trajectory, introducing high-value assets like GALAFOLD and POMBILITI + OPFOLDA. The company reported strong Q2 2026 results, exceeding analyst expectations for both revenue and non-GAAP EPS, and raised its full-year guidance. Investors are now focused on Q3 2026 earnings for further insights into the integration's impact on revenue contribution, operating margins, and the deleveraging timeline.
A third-quarter results call will include a business update from BioMarin’s CEO on Nov. 2.
BioMarin Pharmaceutical (NASDAQ: BMRN) announced it will host its third quarter 2026 financial results conference call and webcast on Monday, November 2, 2026, at 4:30 p.m. ET. President and CEO Alexander Hardy will discuss the results and provide a general business update. A live audio webcast and replay will be available on the company's investor website.
BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET
BioMarin Pharmaceutical Inc. announced it will host a conference call and webcast on Monday, November 2, 2026, at 4:30 p.m. ET to discuss its third quarter 2026 financial results and provide a general business update. The call will feature Alexander Hardy, President and Chief Executive Officer of BioMarin. Interested parties can access the live audio webcast via the investor section of the BioMarin website, with a replay available for one week following the call.